Publication | Closed Access

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

Dolutegravir Versus DarunavirTreatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyVirologyPharmacotherapyHiv-1 InfectionChronic Viral InfectionAntiviral DrugHivMedicineEpidemiologyWeek Results